GW Pharmaceuticals PLC

GW Pharmaceuticals PLC is a biopharmaceutical company that specializes in developing and commercializing innovative therapeutics from its proprietary cannabinoid product platform. Its flagship product, Epidiolex, is the first FDA-approved prescription cannabidiol (CBD) medicine for treating seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients aged two years and above. The company is also working on a pipeline of cannabinoid-based medicines for treating various diseases, such as autism spectrum disorders, glioma, and schizophrenia. GW Pharmaceuticals is dedicated to advancing the science of cannabinoid-based medicines and enhancing the quality of life for patients suffering from debilitating conditions.